Theravance Biopharma (TBPH) Net Income towards Common Stockholders (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of Net Income towards Common Stockholders data on file, last reported at -$5.0 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 63.4% year-over-year to -$5.0 million in Q1 2026; TTM through Mar 2026 was $82.1 million, a 240.79% increase from a year earlier, with the FY2025 full-year figure at $70.1 million, up 224.23% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$5.0 million, down from $28.6 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for TBPH reached as high as $927.1 million in Q3 2022 and fell as low as -$21.7 million in Q1 2023.
• Historically, Net Income towards Common Stockholders has averaged $54.4 million across 5 years, with a median of -$5.3 million in 2023.
• Across the five-year window, Net Income towards Common Stockholders surged 4400.0% in 2022 and tumbled 239.1% in 2023, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at $3.9 million in 2022, then plunged by 236.18% to -$5.3 million in 2023, then tumbled by 192.8% to -$15.5 million in 2024, then soared by 284.5% to $28.6 million in 2025, then sank by 117.35% to -$5.0 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$5.0 million in Q1 2026, $28.6 million in Q4 2025, and $3.6 million in Q3 2025.